BioSpace News Archive

Deals

Botox Maker Allergan Buys Aesthetic Company Bonti for $195 Million Up Front

Dublin-based Allergan is acquiring Newport Beach, California-based Bonti with an upfront payment of $195 million.

September 14, 2018
·
3 min read
·
Mark Terry
Business

Global Joint Venture in Shanghai to Bring Advanced Cell Therapies to Multi-Billion Dollar Patient Population in China

Advanced Cell Therapy Shanghai Summit October 29-31, 2018

September 14, 2018
·
4 min read
Drug Development

Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

Galapagos NV and MorphoSys AG announced today the initiation of a Phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C.

September 14, 2018
·
7 min read
FDA

FDA Gives AstraZeneca’s Lumoxiti a Thumbs-up for Hairy Cell Leukemia

AstraZeneca and its research-and-development arm, MedImmune, announced that the U.S. FDA approved Lumoxiti (moxetumomab pasudotox-tdfk) for adults with relapsed or refractory hairy cell leukemia (HCL) who have had at least two previous systemic therapies, including with a purine nucleoside analog.

September 14, 2018
·
2 min read
·
Mark Terry
Business

Longevity Company Unity Biotechnology Stocks Soared After CEO Talks to CNBC

After Unity Biotechnology chief executive officer Keith Leonard was on CNBC’s “Power Lunch,” touting the company’s therapeutic approach to longevity and aging, company shares soared almost 18 percent.

September 14, 2018
·
3 min read
·
Mark Terry
BioMidwest

Medtech Company Endotronix Snags $45 Million in Series D Funding

Lisle, Ill.-based medtech company Endotronix, Inc. secured $45 million in a Series D financing round. The funds will be used to support the commercialization of its Cordella Heart Failure System and support clinical development of the company’s pulmonary artery sensor.

September 14, 2018
·
2 min read
·
Alex Keown
FDA

FDA Action Alert: Migraine Treatment Approved by the FDA, Ready to Roll in 2 Weeks

The U.S. Food and Drug Administration (FDA) approved Teva Pharmaceutical Industries’ Ajovy (fremanezumab) to prevent migraine on Friday, September 16.

September 14, 2018
·
3 min read
·
Mark Terry
Deals

EMBL Ventures Portfolio Company, ViraTherapeutics Acquired by Boehringer Ingelheim in EUR 210 million (USD 245 million) Transaction

ViraTherapeutics sale marks third exit from EMBL Ventures’ current fund ETF II Heidelberg, Germany, 13th Sept

September 14, 2018
·
5 min read
Recipharm connects to European Hub for serialisation compliance

Recipharm, a leading contract development and manufacturing organisation (CDMO) has successfully received European Medicines Verification Organisation (EMVO) approval to submit serialisation data to the European Hub.

September 14, 2018
·
4 min read
Business

Arix Bioscience appoints Arthur Pappas to the Board of Directors

Arix Bioscience plc today announced that industry veteran Arthur Pappas has been appointed as Non-Executive Director to the Arix Board of Directors.

September 14, 2018
·
4 min read